Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$78.90

-0.9 (-1.13%)

07:33
07/24/17
07/24
07:33
07/24/17
07:33

Walgreens Boots Alliance comments on 340B program

Members of Walgreens Boots Alliance management will be meeting with various investors. During these meetings, in addition to answering general inquiries, the company intends to clarify its participation in the U.S. Health Resources and Services Administration 340B drug pricing program. For the first nine months of fiscal 2017, prescriptions related to the 340B program represented less than 1% of the Retail Pharmacy USA division's prescription volume. The division has around 1,200 340B contracts. During the first nine months of fiscal 2017, 340B prescriptions were filled at approximately 6,100 of the division's pharmacies. 340B prescriptions represented a small percentage of the total prescriptions filled by these pharmacies. The proposal from the U.S. Centers for Medicare and Medicaid Services, announced on July 13, seeks to address how Medicare pays hospitals for drugs acquired under the 340B program, but does not propose eliminating the program altogether. The hospital market represents slightly more than half of the Retail Pharmacy USA division's overall 340B prescriptions. As required by law, 340B drug inventory is owned by the covered entity, not by the pharmacy. On a pro forma basis, for the nine months ended May 31, had the proposed changes to the program been in place throughout the period, the company estimates that the net impact on Retail Pharmacy USA divisional adjusted gross profit dollars would have been less than 0.5%.

WBA Walgreens Boots Alliance
$78.90

-0.9 (-1.13%)

07/20/17
LEER
07/20/17
NO CHANGE
Target $86
LEER
Outperform
Walgreens, Rite Aid deal still facing 'significant hurdle,' says Leerink
Leerink analyst David Larsen says that even though Walgreens Boots Alliance (WBA) and Rite Aid (RAD) restructured their transaction, he still believes it will be difficult to receive FTC approval. Although the asset purchase agreement may address local market concerns, the FTC will still focus on "national markets" and a declining Rite Aid might actually be another headwind, he argues. Larsen reiterates an Outperform rating and $86 price target on Walgreens' shares.
07/17/17
NEED
07/17/17
NO CHANGE
Target $94
NEED
Buy
340B exposure a non-issue for Walgreens Boots Alliance, says Needham
Needham analyst Kevin Caliendo notes that CMS proposed a cut to hospital outpatient reimbursement for the purchase of specialty drugs under the 340B program. The analyst believes Walgreens Boots Alliance has the largest exposure to 340B plans. However, the company said that 340B represented less than 1% of total U.S. pharmacy Rxs for the company, Caliendo adds. He reiterates a Buy rating and $94 price target on the shares.
06/30/17
06/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cabot Oil & Gas (COG) upgraded to Buy from Neutral at BofA/Merrill with analyst Doug Leggate saying Cabot 's gross Marcellus takeaway capacity will increase to 3.7 bcf/d from 2bcf/d by end of 2018 and positioned to increase free cash flow to $2B from $872M per year for 25 years. 2. Becton Dickinson (BDX) upgraded to Strong Buy from Outperform at Raymond James with analyst Lawrence Keusch saying he believes it should be a core holding based an an above average outlook for 5%-6% organic growth and mid-teens earnings increases with further potential upside. 3. Walgreens Boots Alliance (WBA) upgraded to Buy from Hold at Needham. 4. ManTech (MANT) upgraded to Buy from Hold at Loop Capital with analyst Joseph Vafi saying he sees "company-specific and secular catalysts" driving improving fundamentals and upward revisions to consensus estimates. 5. D.R. Horton (DHI) upgraded to Outperform from Market Perform at Raymond James with the firm saying it is uniquely positioned to capitalize on an unexpectedly tight and historically low existing home inventories, while new home demand remains broadly resilient despite rising prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/30/17
COWN
06/30/17
NO CHANGE
Target $5
COWN
Outperform
Rite Aid better positioned following new agreement, says Cowen
Cowen analyst Charles Ryhee said he is positive on the new Rite Aid (RAD) agreement with Walgreens (WBA) as it better positions the company than had it remained stand-alone with no deal at all. Benefits include deleveraging, lower generic procurement costs, increased financial flexibility and "great" leverage toward PBM, which is growing faster than retail. Ryhee reiterated his Outperform rating and $4.70 price target on Rite Aid shares.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$175.00

-1.83 (-1.03%)

07:15
12/15/17
12/15
07:15
12/15/17
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

07:14
12/15/17
12/15
07:14
12/15/17
07:14
Initiation
Rigel Pharmaceuticals initiated  »

Cantor sees FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:12
12/15/17
12/15
07:12
12/15/17
07:12
Downgrade
Criteo rating change  »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

07:11
12/15/17
12/15
07:11
12/15/17
07:11
Recommendations
Oracle analyst commentary  »

Oracle business momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$22.60

2.28 (11.22%)

07:10
12/15/17
12/15
07:10
12/15/17
07:10
Hot Stocks
Innovative Industrial Properties raises quarterly dividend to 25c per share »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$42.96

-0.72 (-1.65%)

07:08
12/15/17
12/15
07:08
12/15/17
07:08
Recommendations
Hologic analyst commentary  »

Hologic positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:07
12/15/17
12/15
07:07
12/15/17
07:07
Earnings
Performance Food Group sees FY18 adjusted EPS up 13%-18% »

For fiscal 2018, PFG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

TYME

Tyme Technologies

$3.30

0.05 (1.54%)

07:05
12/15/17
12/15
07:05
12/15/17
07:05
Initiation
Tyme Technologies initiated  »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Alnylam announces lift of FDA clinical hold on Fitusiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

, UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Upgrade
Under Armour; also tag UAA, Under Armour; also tag UA rating change  »

Under Armour upgraded to…

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBA

Ritchie Bros.

$28.69

0.3 (1.06%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Ritchie Bros. sess $50M+ of equipment in final Fort Worth, TX auction of 2017 »

This week Ritchie Bros.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$43.09

-0.83 (-1.89%)

, ALNY

Alnylam

$123.66

-1.2 (-0.96%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Sanofi says FDA lifts clinical hold on fitusiran »

Sanofi Genzyme, the…

SNY

Sanofi

$43.09

-0.83 (-1.89%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

CROX

Crocs

$10.94

-0.34 (-3.01%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Upgrade
Crocs rating change  »

Crocs upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ESNC

EnSync

$0.44

0.0663 (17.79%)

, CHTR

Charter

$328.68

-0.32 (-0.10%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
EnSync: Spectrum solar plus storage project commissioned in Hawaii »

EnSync (ESNC) announces…

ESNC

EnSync

$0.44

0.0663 (17.79%)

CHTR

Charter

$328.68

-0.32 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Performance Food Group appoints Jim Hope as CFO »

Performance Food Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

07:02
12/15/17
12/15
07:02
12/15/17
07:02
Hot Stocks
Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40% »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

AER

AerCap

$52.12

-0.46 (-0.87%)

07:01
12/15/17
12/15
07:01
12/15/17
07:01
Recommendations
AerCap analyst commentary  »

AerCap book value can hit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$37.30

-0.75 (-1.97%)

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Recommendations
Q2 Holdings analyst commentary  »

Q2 Holdings has strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.82

-0.2 (-2.85%)

06:59
12/15/17
12/15
06:59
12/15/17
06:59
Downgrade
Fitbit rating change  »

Fitbit downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,174.80

10.61 (0.91%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Periodicals
Luxembourg appeals EU order to recover tax from Amazon, Reuters reports »

Luxembourg is appealing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Aclaris Therapeutics »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

GDX

Market Vector Gold Miners

$22.07

-0.09 (-0.41%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$110.57

2.96 (2.75%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Recommendations
Disney, 21st Century Fox analyst commentary  »

Disney price target…

DIS

Disney

$110.57

2.96 (2.75%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

GLD

SPDR Gold Trust

$118.93

-0.24 (-0.20%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.